# Phase 3 prostatic cancer trials recruiting: 80 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 80 trials in phase 3 for prostatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 prostatic cancer trials: 80 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/prostatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 80
- Recruiting or not yet: 80
- Read on: November 19, 2026

## Trials

The 25 newest of 80, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07906717 | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Recruiting | Prostatic Neoplasms | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906717) |
| October 1, 2026 | NCT07853209 | A Phase 3 Study of \[177Lu\]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer | FutureChem | Phase 3 | Recruiting | Prostate Cancer, mCRPC | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853209) |
| September 21, 2026 | NCT07830511 | RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage... | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | Prostate Cancer (Post Prostatectomy), Prostate Cancer, SBRT | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830511) |
| September 3, 2026 | NCT07802704 | A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) \[EMBOLD Prostate-302\] | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Prostate | 684 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802704) |
| August 31, 2026 | NCT07795268 | Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic... | Norroy Bioscience Co., LTD | Phase 3 | Not yet recruiting | Prostate Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795268) |
| August 24, 2026 | NCT07782112 | Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT) | Ente Ospedaliero Cantonale, Bellinzona | Phase 3 | Not yet recruiting | Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782112) |
| August 20, 2026 | NCT07777263 | ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV) | Sponsor not shown (see the record) | Phase 3 | Not yet recruiting | High Risk Prostate Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777263) |
| August 7, 2026 | NCT07751133 | Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer | University College, London | Phase 3 | Recruiting | Prostate Cancer, mHSPC, mCRPC | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751133) |
| July 23, 2026 | NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With... | ORIC Pharmaceuticals | Phase 3 | Recruiting | Metastatic Castration Resistant Prostate Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723248) |
| July 17, 2026 | NCT07711002 | Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy... | AstraZeneca | Phase 3 | Recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 1,330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711002) |
| June 16, 2026 | NCT07649122 | This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate... | Norroy Bioscience Co., LTD | Phase 3 | Recruiting | Prostate Cancer | 232 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649122) |
| June 8, 2026 | NCT07632690 | QLC5508 in Participants With Metastatic Prostate Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Prostate Cancer | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632690) |
| May 29, 2026 | NCT07615101 | Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. | Norroy Bioscience Co., LTD | Phase 3 | Recruiting | Prostate Cancer (Diagnosis) | 365 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615101) |
| May 28, 2026 | NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) | AstraZeneca | Phase 3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07611110) |
| May 20, 2026 | NCT07598032 | Comparative Analysis of Immunological Responses to Vitamin D Replacement Therapy in Black and West African Men Diagnosed With Prostate... | University of Ilorin Teaching Hospital | Phase 3 | Not yet recruiting | Prostate Cancer (Adenocarcinoma), Vitamin D on Tumor Response and Inflammatory Markers | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598032) |
| May 15, 2026 | NCT07591467 | Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer | Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | Not yet recruiting | BRCA-Mutated, Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer, Prostate Cancer | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591467) |
| April 23, 2026 | NCT07548164 | Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer | Memorial Sloan Kettering Cancer Center | Phase 3 | Recruiting | Prostate Cancer | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548164) |
| March 30, 2026 | NCT07500701 | Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in... | Samsung Medical Center | Phase 3 | Recruiting | Prostate Cancer | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07500701) |
| March 17, 2026 | NCT07477626 | Radiotherapy After Prostatectomy for Node Positive Prostate Cancer | Sun Yat-sen University | Phase 3 | Recruiting | Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation... | 372 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477626) |
| February 23, 2026 | NCT07427043 | Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) | Brigham and Women's Hospital | Phase 3 | Recruiting | Opioid Consumption, Postoperative, Multimodal Analgesia, Robotic Assisted Laparoscopic Surgery, Robotic Assisted... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07427043) |
| January 12, 2026 | NCT07333066 | Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Metastatic Hormone-sensitive Prostate Cancer | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07333066) |
| December 19, 2025 | NCT07293585 | Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment | Jonsson Comprehensive Cancer Center | Phase 3 | Recruiting | Prostate Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07293585) |
| December 3, 2025 | NCT07260435 | Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Prostate Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260435) |
| November 10, 2025 | NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Recruiting | Prostatic Neoplasms, Castration-Resistant | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225946) |
| October 9, 2025 | NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic... | Amgen | Phase 3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213674) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| The First Affiliated Hospital with Nanjing Medical University | 3 |
| Norroy Bioscience Co., LTD | 3 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 3 |
| Canadian Cancer Trials Group | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| Gustave Roussy, Cancer Campus, Grand Paris | 2 |
| Alliance for Clinical Trials in Oncology | 2 |
| SWOG Cancer Research Network | 2 |
| UNICANCER | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| M.D. Anderson Cancer Center | 1 |
| University of Rochester | 1 |
| Sun Yat-sen University | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 1 |
| ORIC Pharmaceuticals | 1 |
| Proton Collaborative Group | 1 |
| Yunhe Pharmaceutical (Tianjin) Co., Ltd | 1 |
| Samsung Medical Center | 1 |
| University of Alberta | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | 1 |
| [Telix Pharmaceuticals (Innovations) Pty Limited](https://specstream.ai/data/clinical-trials/company/telix-pharmaceuticals-innovations-pty-limited) | 1 |
| Jonsson Comprehensive Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 37 |
| Canada | 19 |
| France | 18 |
| China | 16 |
| Italy | 14 |
| South Korea | 13 |
| Spain | 13 |
| United Kingdom | 13 |
| Australia | 12 |
| Japan | 12 |
| Germany | 11 |
| Netherlands | 10 |
| Taiwan | 10 |
| Brazil | 9 |
| Switzerland | 9 |
| Belgium | 8 |
| Turkey (Türkiye) | 8 |
| Sweden | 7 |
| Israel | 6 |
| Poland | 6 |
| Puerto Rico | 6 |
| Finland | 5 |
| Hong Kong | 5 |
| Mexico | 5 |
| Singapore | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private schools in the United States](https://specstream.ai/data/businesses/private-schools/united-states)
- [Home inspectors in the United States](https://specstream.ai/data/businesses/home-inspectors/united-states)
- [Cafes in the United States](https://specstream.ai/data/businesses/cafes/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Egyptian restaurants in the United States](https://specstream.ai/data/businesses/egyptian-restaurants/united-states)
